TelyRx Holdings (TELY) investor relations material

Executive summary

• Q3 revenue rose 88% YoY to $23.1M; gross margin expanded to 60% from 56%.

• Recurring-customer revenue reached $17.4M, 75% of sales; the adjusted EBITDA loss narrowed by more than half QoQ to $1.277M, but widened from $0.351M YoY.

Financial highlights

• Gross profit rose to $13.8M from $6.9M YoY; cost of revenue was $9.3M versus $5.5M.

• Net loss was $2.829M versus $1.058M; operating loss was $2.7M versus $0.9M and included $1.0M of non-cash stock-based compensation.

• Q3 basic and diluted loss per share were $0.06 versus $0.10; 9M loss per share was $0.33 versus $0.22.

• Q3 operating cash use was $2.3M versus ~100K; free cash flow was -$3.0M versus -$0.5M YoY.

• 9M revenue was $65.1M versus $28.6M; net loss was $12.0M versus $2.3M.

Outlook and guidance

• Positive adjusted EBITDA remains a near-term goal; Q4 priorities include disciplined investment and profitable, sustainable growth.

• No specific marketing-spend guidance; spending will depend on returns, performance, cash preservation, and market conditions.

• Q4 advertising costs may rise with holiday competition and U.S. midterm political advertising.

• A mobile app planned for Q4 is intended to simplify ordering, refills, and account management and support repeat use.

• Clearwater expansion is expected to more than triple site capacity; timing and budget depend on execution and other assumptions.